Condition: Achondroplasia · Sponsor: QED Therapeutics, a BridgeBio company
This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with ACH. The purposes of the SAD and Phase 2 portions are to identify and confirm the dose of infigratinib to be used in the Phase 2b portion, based on safety and PK. The purpose of the Phase 2b, placebo-controlled portion is to evaluate the safety and efficacy of infigratinib in children \< 3 years old with ACH at the selected dose.
This description comes directly from the study's public registry record.
QED Therapeutics Inc. · 18772805655 · medinfo@qedtx.com
Always discuss trial participation with your own doctor first.
| UCSF Benioff Children's Hospital | Oakland, California, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic | Madison, Wisconsin, United States | Recruiting |
| Murdoch Children's Research Institute | Parkville, Victoria, Australia | Recruiting |
| Children's Hospital of Eastern Ontario Research Institute | Ottawa, Ontario, Canada | Recruiting |
| Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine | Montreal, Quebec, Canada | Recruiting |
| Paediatric Clinical Research Unit at Oslo University Hospital | Oslo, Norway | Recruiting |
| KK Women's and Children's Hospital | Singapore, Singapore | Recruiting |
| Unidad de Cirugía Artroscópica (UCA) | Vitoria-Gasteiz, Spain | Recruiting |
| NHS Greater Glasgow and Clyde | Glasgow, United Kingdom | Recruiting |
| Manchester University NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| Sheffield Children's NHS Foundation Trust | Sheffield, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07169279